The recombinant fusion protein vaccine construct is composed of (i) a cell-penetrating peptide (CPP) conferring enhanced vaccine delivery, promoting efficient antigen loading allowing presentation on both major histocompatibility complex (MHC) class I and II molecules [1], (ii) a multi-antigenic domain (Mad), rationally designed containing CD8 and CD4 epitopes from different tumor-specific antigens across a range of HLA restrictions and (iii) a TLR2/4 agonist peptide, which confers self-adjuvant activity to the vaccine [2]. The gene discussed is CD4; the disease is neoplasm.